Business EconomyPosted at: Oct 1 2026 11:32PM


Acrotech Biopharma launches ADQUEY in US, enters dermatology market

Hyderabad, Sep 30 (UNI) Acrotech Biopharma Inc, , a subsidiary of Hyderabad based Aurobindo Pharma, on Thursday announced the launch of ADQUEY (difamilast 1%) ointment in the US for the treatment of mild-to-moderate atopic dermatitis in adults and children aged two years and above.
The non-steroidal topical phosphodiesterase 4 (PDE4) inhibitor is intended for patients with atopic dermatitis, a chronic inflammatory skin condition, the pharma company said in a release.
The product was originally discovered and developed by Otsuka Pharmaceutical Co Ltd and licensed to Acrotech Biopharma for commercialisation in the US.
The launch marks Acrotech's entry into the US dermatology market.
The company has also established a dedicated dermatology business unit with specialised marketing, sales and field-based capabilities to support healthcare professionals and improve patient access to treatment.
According to IQVIA data cited by the company, the US market for atopic dermatitis treatments was estimated at around USD 1.3 billion for the 12 months ending July 2026.
"The launch of ADQUEY is an important milestone for Acrotech and marks our entry into the US dermatology market with a differentiated treatment option for patients living with atopic dermatitis," said Ashish Anvekar, President of Acrotech Biopharma.
He said the company was building a dedicated dermatology platform to support the product's launch and pursue further opportunities to address unmet needs in dermatological care.
The new business unit will focus on raising awareness of ADQUEY, engaging with dermatology healthcare professionals and supporting patients throughout their treatment journey, while developing capabilities to expand the company's presence in the specialty dermatology market.
The launch is part of Acrotech's strategy to expand its portfolio of proprietary medicines and establish specialised commercial platforms in therapeutic areas with significant patient needs.
UNI KNR RN
Please log in to get detailed story.
Tags: #Acrotech Biopharma launches ADQUEY in US# enters dermatology market
More News

L&T bags big power transmission orders in Saudi Arabia, UAE

05 Oct 2026 | 4:38 PM

New Delhi, Oct 5 (UNI) Larsen & Toubro (L&T) on Monday said its Power Transmission & Distribution (PT&D) business has secured multiple engineering, procurement and construction (EPC) orders in India and overseas, with a focus on strengthening electricity transmission networks and supporting renewable energy integration.

see more..

TVS ASL attracts strategic investment from UAE-based Crescent Enterprises

05 Oct 2026 | 4:33 PM

Chennai, Oct 5 (UNI) TVS Automobile Solutions (TVS ASL), the owner of the ‘myTVS’ automotive aftermarket brand and part of the USD 3 billion TVS Mobility Group, today announced that it has raised Rs.425 crore in a Series D funding round led by CE-Invests, the strategic investment arm of UAE-based Crescent Enterprises.

see more..

SAIL achieves record production, sales in H1 FY27; high-end steel output jumps 30 pc

05 Oct 2026 | 1:03 PM

New Delhi, Oct 5 (UNI) Steel Authority of India Limited (SAIL) has delivered a remarkable performance in the first half of FY27 (April-September 2026) and in September 2026, achieving several best-ever milestones across production, sales and efficiency parameters.

see more..

AM Intelligence expands Nvidia Vera Rubin AI factory capacity in India, Malaysia

05 Oct 2026 | 12:23 PM

Hyderabad, Oct 5 (UNI) AM Intelligence (AMI), the AI infrastructure platform set up by the promoters of Greenko, on Monday announced two further firm and binding orders for 20,000 NVIDIA Rubin GPUs to be deployed as NVIDIA Vera Rubin NVL72 rack-scale systems in India and Malaysia.

see more..

Taiwan-based air carrier set to launch direct flights from Delhi to Taipei

04 Oct 2026 | 9:53 PM

New Delhi, Oct 4 (UNI) Set to become the only Taiwan-based airline to operate direct flights from Delhi to Taipei, EVA Air is geared up to launch the service starting December 1, officals said. .

see more..